Xintela AB (OSTO:XINT) Common Stock : kr17.06 Mil (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Xintela AB Common Stock?

Xintela AB's quarterly common stock increased from Mar. 2024 (kr17.01 Mil) to Jun. 2024 (kr17.06 Mil) but then stayed the same from Jun. 2024 (kr17.06 Mil) to Sep. 2024 (kr17.06 Mil).

Xintela AB's annual common stock increased from Dec. 2021 (kr2.67 Mil) to Dec. 2022 (kr9.23 Mil) and increased from Dec. 2022 (kr9.23 Mil) to Dec. 2023 (kr17.01 Mil).

Xintela AB Common Stock Historical Data

The historical data trend for Xintela AB's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xintela AB Common Stock Chart

Xintela AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

1.18

2.22

2.67

9.23

17.01

Xintela AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial															16.38	17.01	17.01	17.06	17.06

Xintela AB Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Xintela AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xintela AB (OSTO:XINT) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Medicon Village, Lund, SWE, 22381

Website

https://www.xintela.se

Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.

Xintela AB Headlines

No Headlines